Carregant...
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B...
Guardat en:
| Publicat a: | Leukemia |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7862069/ https://ncbi.nlm.nih.gov/pubmed/33122850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-01072-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|